XML 43 R31.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION: (Tables)

9 Months Ended

Dec. 31, 2020

Schedule of stock-based compensation activity, by award type

The Company's stock-based compensation activity for the nine months ended December 31, 2020, by award type, was (dollars in millions):


	For the nine months ended
	December 31,
	2020		2019
Stock options	$	1.9	$	2.8

Restricted stock units	40.5		40.5
Arbor acquisition consideration holdback	—		2.6
DPM acquisition consideration holdback	6.0		4.1
PDP assumed performance plan	13.8		21.4
Acuity performance plan	1.4		—
Other stock-based compensation	1.0		0.9
Total non-cash stock-based compensation included in the condensed consolidated statements of operations	64.6		72.3
Less expense related to liability-based equity awards	(19.7)		(23.3)

Total non-cash stock-based compensation included in the condensed consolidated statements of equity	$	44.9	$	49.0

Schedule of effect of stock-based compensation expense on income, by financial statement line item

The effect of stock-based compensation expense on income, by financial statement line item, was (dollars in millions):


	For the nine months ended
	December 31,
	2020		2019
Cost of revenue	$	2.7	$	2.8
Research and development	21.0		17.3
Sales and marketing	25.6		34.4
General and administrative	15.3		17.8
Total non-cash stock-based compensation included in the condensed consolidated statements of operations	$	64.6	$	72.3

Schedule of share based compensation arrangement by share based payment award, future expense

The following table provides the expected future expense for all of the Company's outstanding equity awards at December 31, 2020, by award type. The amount for 2021 represents the remaining three months ending March 31, 2021. All other periods represent fiscal years ending March 31 (dollars in millions).


	For the years ending March 31,
	2021		2022		2023		2024		2025		Total
Stock options	$	0.3	$	1.1	$	0.3	$	—	$	—	$	1.7
Restricted stock units	59.4		42.9		43.9		24.1		4.4		174.7
DPM acquisition consideration holdback	2.0		8.1		2.1		—		—		12.2
PDP assumed performance plan	4.6		9.2		—		—		—		13.8
Acuity performance plan	0.8		1.9		0.8		0.2		—		3.7
Other stock-based compensation	0.6		0.4		—		—		—		1.0
	$	67.7	$	63.6	$	47.1	$	24.3	$	4.4	$	207.1

Schedule of option activity

Stock option activity for the nine months ended December 31, 2020 was:


				Weighted-average
		Weighted-average		remaining	Aggregate
	Number of	exercise price		contractual term	Intrinsic value
	shares	per share		(in years)	(in thousands)
Outstanding at March 31, 2020	1,350,658	$	14.43

Exercised	(524,085)	$	12.37		$	22,271
Forfeited or canceled	(6,124)	$	5.24
Outstanding at December 31, 2020	820,449	$	15.81	3.4	$	47,075
Exercisable at December 31, 2020	783,303	$	16.47	3.2	$	44,431

Summary of stock options outstanding and exercisable

A summary of stock options outstanding and exercisable as of December 31, 2020 was:


					Options outstanding				Options exercisable
Range of						Weighted-average	Weighted-average			Weighted-average
exercise price					Options	remaining	exercise price		Options	exercise price
per share					outstanding	contractual life	per share		exercisable	per share
$	0.61	—	$	9.99	125,984	4.6 years	$	1.52	88,838	$	1.32
$	10.00	—	$	19.99	346,807	3.0 years	$	15.50	346,807	$	15.50
$	20.00	—	$	24.99	347,658	3.3 years	$	21.31	347,658	$	21.31

					820,449	3.4 years	$	15.81	783,303	$	16.47

Schedule of time-vesting restricted stock unit activity

RSU activity for the nine months ended December 31, 2020 was:


		Weighted-average
		fair value per		Weighted-average
	Number	share at grant		remaining contractual
	of shares	date		term (in years)
Outstanding at March 31, 2020	3,351,638	$	40.68	2.51
Granted	1,969,500	$	41.36
Vested	(1,011,380)	$	41.43
Forfeited or canceled	(459,731)	$	41.35
Outstanding at December 31, 2020	3,850,027	$	40.75	2.57

Schedule of non-vested performance-based restricted stock units activity

PSU activity for the nine months ended December 31, 2020 was:


		Weighted-average
		fair value per		Weighted-average
	Number	share at grant		remaining contractual
	of shares	date		term (in years)
Outstanding at March 31, 2020	545,446	$	51.01	2.24
Granted	246,524	$	43.40
Additional earned performance shares	38,063	$	55.48
Vested	(121,587)	$	48.88
Forfeited or canceled	(34,731)	$	34.94
Outstanding at December 31, 2020	673,715	$	49.69	1.78